Study design and setting
We did a phase II, single-centered, randomized, double-blind, parallel groups, placebo-controlled clinical trial of FAKHRAVAC inactivated SARS-CoV-2 vaccine on adults aged 18 to 70. The study protocol was approved by the National Ethics Committee for Research in Medical Sciences (approval number IR.NREC.1400.003, June 8, 2021). The trial was registered in the Iranian Registry of Clinical Trials [